| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Serves as a circulating serum and serum exosomal biomarker candidate for discriminating NSCLC from benign lung tumor and is associated with aggressive clinicopathological features including higher stage, lymph node metastasis and distant metastasis. |
| Molecular mechanism: |
No disease mechanism was experimentally defined in NSCLC; the study focused on serum and serum exosomal expression and diagnostic/clinicopathological associations. |
| Biological pathway or process: |
metastasis (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Serum and serum exosomal hsa_circ_0069313 can discriminate NSCLC from benign lung tumor; higher serum exosomal levels are linked to stage III-IV, lymph node metastasis and distant metastasis. |
| Description: |
hsa_circ_0069313 was validated by qRT-PCR as up-regulated in serum and serum exosomes of NSCLC patients. Its serum and serum exosomal levels showed diagnostic potential for distinguishing NSCLC from benign lung tumor, and higher serum exosomal levels were associated with more aggressive NSCLC features including advanced stage and metastasis. |
| Confidence score: |
0.5047 |